Verification of the Optimal Interval Before Esophagectomy After Preoperative Neoadjuvant Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer-Reference-Cited by-同舟云学术

Verification of the Optimal Interval Before Esophagectomy After Preoperative Neoadjuvant Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer

Published:2020-10-13 Issue:4 Volume:28 Page:2101-2110
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Wakita Akiyuki,Motoyama Satoru,Sato Yusuke,Nagaki Yushi,Fujita Hiromu,Terata Kaori,Imai Kazuhiro,Minamiya Yoshihiro

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-020-09206-x.pdf

Reference33 articles.

1. Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360–73.

2. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 2000;232(2):225–32.

3. Shitara K, Muro K. Chemoradiotherapy for treatment of esophageal cancer in Japan: current status and perspectives. Gastrointest Cancer Res. 2009;3(2):66–72.

4. Tachimori Y, Ozawa S, Numasaki H, et al. Registration Committee for Esophageal Cancer of the Japan Esophageal Society. Comprehensive registry of esophageal cancer in Japan, 2012. Esophagus. 2019;16(3):221–45.

5. Motoyama S, Sugiyama T, Ueno Y, et al. REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy. Ann Surg Oncol. 2006;13(12):1724–31.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant treatment patterns for pT3N0M0 esophageal cancer undergoing surgery;Diseases of the Esophagus;2024-03-28

2. Early versus delayed surgery following neoadjuvant chemoradiation for esophageal cancer: a systematic review and meta-analysis;Esophagus;2023-02-17

3. Immune checkpoint inhibitors in the treatment of oesophageal squamous cell carcinoma: where are we and where are we going?;Therapeutic Advances in Medical Oncology;2023-01

4. The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review;Frontiers in Oncology;2022-07-14

5. Association between ABCC2 polymorphism and hematological toxicity in patients with esophageal cancer receiving platinum plus 5-fluorouracil therapy;Esophagus;2021-08-04